Loading...
XSHE
300683
Market cap546mUSD
Dec 05, Last price  
29.51CNY
1D
0.99%
1Q
-30.97%
IPO
-42.92%
Name

Wuhan Hiteck Biological Pharma Co Ltd

Chart & Performance

D1W1MN
XSHE:300683 chart
P/E
P/S
5.95
EPS
Div Yield, %
Shrs. gr., 5y
4.83%
Rev. gr., 5y
0.91%
Revenues
649m
+7.75%
355,992,686548,791,132679,406,628770,974,124750,258,800590,873,499620,163,188524,123,427614,683,452688,625,991602,284,306648,974,123
Net income
-69m
L-42.60%
77,654,086109,911,99583,346,512157,053,448142,389,64994,137,74563,035,065027,654,2280-120,822,819-69,348,658
CFO
23m
+326.89%
76,821,220135,404,687159,887,188143,859,87183,076,51173,423,47963,027,543012,088,24753,033,6645,314,25722,685,841
Dividend
Jul 01, 20200.16 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
IPO date
Aug 08, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT